Treatment gap in the management of hypercholesterolemia in Korea: Return on Expenditure Achieved for LIpid TherapY (REALITY)

Korean Circulation Journal

Volumn 36, Issue 8, 2006, Pages 593-599

  Kim, Sang Hyun ^a,b   Park, Jin Shik ^a,c   Zo, Joo Hee ^a,b   Kim, Myung A ^a,b   Kim, Hyo Soo ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Coronary disease; Guideline; Hypercholesterolemia

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KOREA; LIPID BLOOD LEVEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 33748787729     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2006.36.8.593     Document Type: Article

References (18)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult Treatment Panel (ATP) III. JAMA 2001;285:2486-97.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
3. Committee of Treatment Guideline for Hypercholesterolemia. Treatment guideline for hypercholesterolemia. 2nd ed. Korean Society of Lipidology and Atherosclerosis; 2003.
4. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997;80:45H-52H.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000;160:459-67.
6. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II (European Action on Secondary Prevention through Intervention to Reduce Events) Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
7. Keech A, Zambahary R, Ritchie G, et al. Hypercholesterolaemia as a risk factor for coronary heart disease in the Asia-Pacific region: the ASPAC study. Atherosclerosis 2000;151:83. Abstract
8. Cohen MV, Byrne MJ, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991;83:1294-304.
9. Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J Am Coll Cardiol 1997;29:139-46.
10. Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol 1998;81:1416-20.
11. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999;83:1303-7.
12. Ruof J, Klein G, Marz W, Wollschlager H, Neiss A, Wehling M. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 2002;35:48-53.
13. Samaha LA. The American Heart Association Get with the Guidelines program. Am Heart J 2004;148:546-8.
14. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative. JAMA 2002;287:1269-76.
15. Lee YW. Present Status and Treatment of Hyperlipidemia. Korean Circulation J 1991;21:467-73.
16. Ko JY, Yoon JH, Kim JY, et al. Reconsideration of the current guidelines for lipid-lowering therapy in patients with coronary artery disease. Korean Circ J 2001;31:767-72.
17. Kim JM, Kwon GH, Lim SJ, et al. A study on the achievement of NCEP - ATP II goal of cholesterol lowering therapy. Korean J Lipidol Atheroscler 2001;11:181-9.
18. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13.